# Mayim Bialik's GLP-1 Experience Highlights Severe GI Side Effects
Actress and neuroscientist Mayim Bialik recently shared that she experienced "uncontrollable" gastrointestinal symptoms while taking GLP-1 receptor agonist medications. The class of drugs, which includes semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro), has gained widespread popularity for weight loss and diabetes management.
GLP-1 medications work by slowing gastric emptying and affecting appetite regulation in the brain. This mechanism produces weight loss but frequently causes nausea, vomiting, constipation, and diarrhea. Bialik's experience aligns with clinical trial data showing that gastrointestinal distress affects a substantial portion of users.
The FDA has documented these side effects extensively. In clinical trials for semaglutide, nausea occurred in up to 25 percent of participants, while vomiting affected roughly 11 percent. Gastrointestinal symptoms typically emerge early in treatment and often improve over time as the body adjusts. However, some patients experience persistent or worsening symptoms that necessitate dose reduction or medication discontinuation.
Healthcare providers increasingly emphasize that GLP-1 medications are not appropriate for everyone. Dr. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital, stresses that careful patient selection and close monitoring reduce adverse outcomes. Starting with the lowest possible dose and titrating slowly gives the body time to adapt.
Bialik's candid disclosure reflects broader conversations about medication tolerability. While GLP-1 drugs deliver significant metabolic benefits for many users, the gastrointestinal burden varies widely between individuals. Some manage mild symptoms